Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma

BACKGROUND: Patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) or R/R systemic anaplastic large-cell lymphoma (sALCL) treated with brentuximab vedotin (BV) experienced high remission rates in two Phase II trials. With increased response rates and survival times, patient-reported outcomes...

詳細記述

保存先:
書誌詳細
出版年:Onco Targets Ther
主要な著者: Chen, Robert, Allibone, Suzanne, Bartlett, Nancy L, Brice, Pauline, Chen, Andy, Pose, Katrina, Rich, Lynn, Bonthapally, Vijay, Garfin, Phillip M, Fanale, Michelle
フォーマット: Artigo
言語:Inglês
出版事項: Dove Medical Press 2016
主題:
Original Research
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4827881/
https://ncbi.nlm.nih.gov/pubmed/27103829
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S96175
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料